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Introduction {#sec006}
============

Hepatitis B virus (HBV) infection is one of the most common infectious diseases worldwide. Approximately one third of the world population has been exposed to the virus and an estimated 257 million people are chronically infected \[[@pone.0234740.ref001]\]. Regardless of the asymptomatic nature of chronic HBV infection, patients remain infectious to others and are at risk of death from cirrhosis and hepatocellular carcinoma \[[@pone.0234740.ref001]\]. In 2015, HBV-related complications accounted for 887,000 deaths globally \[[@pone.0234740.ref001]\].

The possibilities for antiviral treatment of chronic HBV infection have greatly improved over the past decades, and cost-effective drug therapies are now available \[[@pone.0234740.ref002], [@pone.0234740.ref003]\]. However, due to the asymptomatic course, most patients are unaware of their HBV infection and do not benefit from treatment. Screening for hepatitis B, aimed at early detection of chronic HBV infection with follow-up and antiviral treatment of eligible patients, is needed to reduce the economic burden of HBV-related complications and health-related suffering in Europe \[[@pone.0234740.ref004], [@pone.0234740.ref005]\]. In addition, screening could identify persons who are susceptible to infection and would benefit from vaccination \[[@pone.0234740.ref005]\].

In low endemic countries (\< 2% hepatitis B surface antigen (HBsAg) positive), migrants born in intermediate (2--7.99% HBsAg positive) or high endemic (≥ 8% HBsAg positive) regions are an important risk group for chronic HBV infection \[[@pone.0234740.ref006]\]. In Belgium, the prevalence of chronic HBV infection is estimated to be 0.67% in the general population and 4.69% in first-generation migrants (FGM) born in intermediate or high endemic countries \[[@pone.0234740.ref006]--[@pone.0234740.ref008]\]. Migrants from intermediate or high endemic countries account for more than half of the patients with chronic HBV infection in Belgium \[[@pone.0234740.ref009]\]. Turkish individuals form the second largest FGM population in Europe and with a HBsAg prevalence in Turkey ranging from 2--3% in the Western part up to 7--8% in Eastern part, a substantial proportion of the Turkish migrant population may be infected with HBV \[[@pone.0234740.ref009], [@pone.0234740.ref010]\].

Most studies concerning hepatitis B testing in FGM involved southeast Asians in the USA, Canada and Australia \[[@pone.0234740.ref011]\]. A cross-sectional study in Turkish FGM in Germany showed a prevalence of 5% for chronic HBV infection, and this was 3% in a study conducted in the Netherlands \[[@pone.0234740.ref012], [@pone.0234740.ref013]\]. However, HBV risk factors and follow-up in Turkish FGM are mostly unclear. Furthermore, much less is known about infection prevalence, risk factors and follow-up in second-generation migrants (SGM), i.e. born in Belgium with a foreign-born parent. This is all the more important as the descendants of the FGM population grow. Regarding acute hepatitis B notification rates, a Dutch study showed a higher rate of 3.7/100,000 in SGM compared with 1.6/100,000 in native Dutch/Western persons \[[@pone.0234740.ref014]\].

We organized a hepatitis B testing and risk factor assessment campaign for the Turkish population in Middle Limburg, Belgium, a region with a relatively large Turkish population \[[@pone.0234740.ref015]\]. Here we report the prevalence of HBV infection in individuals with a Turkish background (FGM and SGM), the results of a questionnaire on risk factors, and the follow-up of patients referred to care.

Patients and methods {#sec007}
====================

From 1 September 2017 until 2 May 2019, we recruited ≥ 18 year-old Turkish migrants living in the region Middle Limburg. Follow-up was concluded on 2 November 2019, 6 months after the last inclusion. The study methods have been published previously \[[@pone.0234740.ref016]\]. In brief, educational hepatitis B sessions with the possibility for immediate HBV screening were scheduled after the regular meetings of Turkish organizations (e.g. Islamic mosque) located in Middle Limburg. Turkish migrants could also contact the culturally targeted, multilingual (Dutch-, English- and Turkish-speaking) first author for home visits and/or for an appointment at the hepatology outpatient clinic to sign an informed consent and be screened for HBV infection. The free outreach hepatitis B testing campaign was combined with risk factor assessment by a face-to-face questionnaire. Blood samples were tested for HBsAg, antibodies against HBsAg (anti-HBs) and hepatitis B core antibodies (anti-HBc) with an electrochemiluminescence assay (Cobas 8000 e602, Roche, Germany). Both participants and their general practitioner received the test result by letter and, supplementary to this, the general practitioners were advised to contact the HBsAg positive participants by phone. All patients who tested positive for HBsAg were referred to a hepatologist for a clinical work-up and treatment program according to the European clinical practice guidelines \[[@pone.0234740.ref017]\]. HBsAg positive patients were divided in four phases, taking into account the presence of hepatitis B e antigen (HBeAg), serum HBV DNA levels and serum alanine aminotransferase (ALT) values \[[@pone.0234740.ref017]\]. Persons susceptible to HBV infection were asked to consult their general practitioner for HBV vaccination.

Questionnaire {#sec008}
-------------

Before hepatitis B testing, HBV risk factors were assessed through a face-to-face questionnaire ([S1](#pone.0234740.s001){ref-type="supplementary-material"}--[S6](#pone.0234740.s006){ref-type="supplementary-material"} Figs). The questionnaire was available in the Dutch or Turkish language, and covered a total of 23 and 21 questions for males and females, respectively. The questionnaire did not cover information on intravenous drug use or sexual behaviour as these questions are sensitive and therefore socially censured; pressure to conform to societal norms could cause self-reports to be fraught with bias.

Statistical analysis {#sec009}
--------------------

The sample size calculation was performed with the aid of Epi Info^®^ (version 7.2). Since data on country of birth in Middle Limburg are unavailable and data on nationality do not represent country of birth, the number of study participants per age group was calculated so that the results of the study group agree with that of the Turkish population living in Middle Limburg with a significance level of 5%. This is important for the extrapolation of the study results to the general Turkish population ([Table 1](#pone.0234740.t001){ref-type="table"}).

10.1371/journal.pone.0234740.t001

###### Composition of the study group compared with the composition of the Turkish population living in Middle Limburg regarding age and gender.
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  Age (years)                             Total   18--39   40--59   ≥ 60   Male   Female
  --------------------------------------- ------- -------- -------- ------ ------ --------
  Study group (N)                         1,081   433      511      137    468    613
  Study group (%)                         100     40.1     47.3     12.6   43.3   56.7
  Turkish Middle Limburg population (%)   100     53.9     35.4     10.7   50.5   49.5

To assess the impact of universal HBV vaccination in Belgium among Turkish SGM, we stratified HBsAg, anti-HBc and/or anti-HBs prevalence into two birth cohorts (1930--1986 and 1987--2001). This cutoff was chosen as the free-of-charge HBV vaccination program in infants since September 1999 with catch-up vaccination for 10--13 year-olds covered children born after 1987 in Belgium \[[@pone.0234740.ref018]\].

Since participants could be part of the same household, resulting in violation of the assumption of independent observations for classical tests such as logistic regression, univariate generalized estimating equations (GEE) were used to investigate the influence of the different variables on the presence of past or current HBV infection (anti-HBc positive), chronic HBV infection (HBsAg positive) and vaccination status (solely anti-HBs positive). The correlation structure in these GEE is assumed to be of the 'compound symmetry' type, specifying that all observations within the same cluster are equally correlated. Although this might not be the correct assumption, GEE has been shown to be robust to misspecification of the working correlation structure \[[@pone.0234740.ref019]\].

Variables showing significant association (*p* \< .20) in the univariate analyses were subsequently included in a multiple GEE model. As origin and educational level of mother and father were highly correlated, only maternal factors were included in the models. Backward selection was used to obtain a final model. In order to correct for differences between the sample and the Middle-Limburg population, weights were included in all GEE models. Weighting was done based on the combination of age and gender.

Ethical approval {#sec010}
----------------

The study was undertaken in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the medical ethics committees of Hasselt University and Hospital East-Limburg (17-039U). All participants gave their informed consent in writing prior to inclusion.

Results {#sec011}
=======

In total 1,081 Turkish migrants were tested for HBV infection; 1,047 of the 1,079 (97.0%) persons present at the educational meetings in a Turkish organization and all 34 (100.0%) participants present at home visits did go for testing. Less than half of the study participants were male (43.3%), and the mean age was 44 ± 13.7 years. The majority of the participants were born in Turkey (58.1%), 41.9% were born in Belgium.

Blood samples were insufficient for anti-HBs testing in four participants. In 21.5% (232/1,081) there was evidence of a past or recent HBV infection (anti-HBc positive), 2.4% (26/1,081) had a chronic HBV infection (HBsAg positive), 22.9% (247/1,077) of the samples were solely anti-HBs positive ('vaccinated' serostatus) and 55.5% (598/1,077) appeared to be susceptible for HBV infection (negative HBV markers).

Past or recent HBV infection {#sec012}
----------------------------

Past or recent HBV infection in FGM was apparent in 206/628 (32.8%) with differences between males and females, i.e. 40.4% (110/272) vs 27.0% (96/356), respectively, *p* = .001. Among FGM, anti-HBc prevalence in 18--39 year-olds, 40--59 year-olds and \>60 year-olds was 13.2% (14/106), 31.9% (123/385) and 50.4% (69/137), respectively, *p* \< .001.

Gender difference regarding anti-HBc prevalence was not seen in Turkish SGM, i.e. 5.6% (11/196) in males vs 5.8% (15/257) in females, *p* = 1.000. Anti-HBc prevalence in Turkish SGM born after 1987 was 1.1% (2/190), and was higher for those SGM born before 1987, i.e. 9.1% (24/263), *p* \< .001. Older age was associated with past or recent HBV infection in SGM, i.e. 4.0% (13/327) in 18--39 year-olds vs 10.3% (13/126) in 40--59 year-olds, *p* = .018. There were no SGM 60 years or older.

Factors associated with past or recent HBV infection in the weighted univariate GEE are shown in [Table 2](#pone.0234740.t002){ref-type="table"}. From the weighted multiple GEE analyses as shown in [Table 3](#pone.0234740.t003){ref-type="table"}, it can be seen that male gender (*p* = .021), older age (*p* \< .001), FGM (*p* \< .001), lower (i.e. none or primary) educational level of the mother (*p* = .003), HBV infected mother (*p* = .008), HBV infected siblings (*p* = .002), HBV infected other family member (*p* = .004), gynaecological examination in Turkey or unsafe male circumcision (*p* = .032), dental treatment in Turkey (*p* = .049), and treatment with needles in Turkey (*p* = .012) significantly increased the odds of anti-HBc positivity.

10.1371/journal.pone.0234740.t002

###### Prevalence of past or recent hepatitis B virus infection by different risk factors among the total study population (n = 1,081) (weighted univariate GEE).
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                                                                     n     N       Prevalence (%)   *P* value   Crude OR (95% CI)
  ------------------------------------------------------------------ ----- ------- ---------------- ----------- ---------------------
  Overall                                                            232   1,081   21.5%            \-          \-
  Gender                                                                                            .038        
   Male                                                              121   468     25.9%                        1.38 (1.02--1.86)
   Female                                                            111   613     18.1%                        (ref)
  Age group                                                                                         \< .001     
   18--39 years                                                      27    433     6.2%                         (ref)
   40--59 years                                                      136   511     26.6%                        5.73 (3.67--8.92)
   ≥ 60 years                                                        69    137     50.4%                        16.26 (9.55--27.67)
  Ethnicity                                                                                         \< .001     
   FGM                                                               206   628     32.8%                        8.84 (5.59--13.97)
   SGM                                                               26    453     5.7%                         (ref)
  Year of immigration (if FGM)                                                                      \< .001     
   Before 1987                                                       144   363     39.7%                        2.33 (1.58--3.42)
   Year 1987 or later                                                61    264     23.1%                        (ref)
  Southeastern Anatolian origin of mother                                                           .470        
   Yes                                                               15    59      25.4%                        1.28 (0.68--2.42)
   No                                                                216   971     22.2%                        (ref)
  Mother's educational level                                                                        \< .001     
   None                                                              167   570     29.3%                        7.65 (0.96--60.73)
   Primary school                                                    61    380     16.5%                        3.57 (0.45--28.64)
   Secondary school                                                  3     123     2.4%                         0.37 (0.03--4.15)
   High school/University                                            1     13      7.7%                         (ref)
  HBV infected partner                                                                              .698        
   Yes                                                               7     25      28.0%                        1.23 (0.43--3.50)
   No/Unknown                                                        225   1,056   21.3%                        (ref)
  HBV infected mother                                                                               .005        
   Yes                                                               17    37      45.9%                        4.21 (1.98--8.99)
   No/Unknown                                                        215   1,044   20.6%                        (ref)
  HBV infected father                                                                               .016        
   Yes                                                               2     24      8.3%                         0.24 (0.05--1.17)
   No/Unknown                                                        230   1,057   21.8%                        (ref)
  HBV infected siblings                                                                             .003        
   Yes                                                               21    45      46.7%                        3.77 (1.81--7.87)
   No/Unknown                                                        211   1,036   20.4%                        (ref)
  HBV infected other family member                                                                  .008        
   Yes                                                               26    70      37.1%                        2.65 (1.47--4.80)
   No/Unknown                                                        206   1,011   20.4%                        (ref)
  Sharing toothbrushes regularly                                                                    \< .001     
   Yes                                                               62    188     33.0%                        2.35 (1.59--3.47)
   No                                                                170   892     19.1%                        (ref)
  Sharing nail clippers                                                                             .296        
   Yes                                                               208   991     21.0%                        0.74 (0.43--1.25)
   No                                                                24    89      27.0%                        (ref)
  Sharing razors                                                                                    .609        
   Yes                                                               36    170     21.2%                        1.13 (0.73--1.75)
   No                                                                196   910     21.5%                        (ref)
  Sharing used towels                                                                               .164        
   Yes                                                               206   945     21.8%                        1.38 (0.85--2.24)
   No                                                                26    135     19.3%                        (ref)
  Eating from the same plate                                                                        .423        
   Yes                                                               201   927     21.7%                        1.19 (0.77--1.84)
   No                                                                31    153     20.3%                        (ref)
  Gynaecological examination in Turkey (if female)                                                  .003        
   Yes                                                               30    99      30.3%                        2.73 (1.60--4.67)
   No                                                                81    514     15.8%                        (ref)
  Circumcision (if male)                                                                            .004        
   Collective                                                        44    118     37.3%                        2.18 (1.34--3.56)
   Alone                                                             66    305     21.6%                        (ref)
  Circumcision not carried out by medical doctor (if male)                                          \< .001     
   Yes                                                               84    228     36.8%                        5.24 (2.76--9.94)
   No                                                                14    153     9.2%                         (ref)
  Gynaecological examination in Turkey or unsafe male circumcision                                  \< .001     
   Yes                                                               115   330     34.9%                        2.92 (2.12--4.02)
   No                                                                117   751     15.6%                        (ref)
  Blood transfusion                                                                                 .062        
   Yes                                                               44    167     26.3%                        1.52 (1.01--2.27)
   No                                                                188   914     20.6%                        (ref)
  Dental treatment in Turkey                                                                        \< .001     
   Yes                                                               147   430     34.2%                        4.36 (3.17--5.98)
   No                                                                85    651     13.1%                        (ref)
  Surgery in Turkey                                                                                 \< .001     
   Yes                                                               50    133     37.6%                        3.12 (2.05--4.76)
   No                                                                182   948     19.2%                        (ref)
  Treatment with needles in Turkey                                                                  \< .001     
   Yes                                                               107   322     33.2%                        2.82 (2.04--3.91)
   No                                                                125   759     16.5%                        (ref)
  Body piercing/tattooing/earlobe perforation in Turkey                                             .009        
   Yes                                                               84    327     25.7%                        1.58 (1.14--2.20)
   No                                                                148   754     19.6%                        (ref)
  Fish spa treatment                                                                                .058        
   Yes in Turkey                                                     9     64      14.1%                        0.54 (0.25--1.14)
   No/Other                                                          223   1,017   21.9%                        (ref)

Abbreviation: GEE: generalized estimating equations; OR: odds ratio; CI: confidence interval; HBV: hepatitis B virus; FGM: first-generation migrants; SGM: second-generation migrants.

First-generation migrants: foreign-born individuals; second-generation migrants: individuals born in Belgium with foreign-born parents; unsafe male circumcision: collective circumcision and/or circumcision not carried out by medical doctor.

10.1371/journal.pone.0234740.t003

###### Association of past or recent hepatitis B virus infection to different risk factors among the total study population (n = 1,081) (weighted multiple GEE model).
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  Parameter                                                                                                  Estimate (SE)   *p*-value   aOR (95% CI)
  ------------------------------------------------------------------ --------------------------------------- --------------- ----------- --------------------
  (intercept)                                                                                                -4.39 (0.79)                
  Gender                                                                                                                     .021        
                                                                     Male (vs Female)                        0.46 (0.19)                 1.58 (1.08--2.31)
  Age group                                                                                                                  \< .001     
                                                                     40--59 years (vs 18--39 years)          0.80 (0.25)                 2.21 (1.36--3.62)
                                                                     ≥ 60 years (vs 18--39 years)            1.50 (0.32)                 4.50 (2.39--8.47)
  Ethnicity                                                                                                                  \< .001     
                                                                     FGM (vs SGM)                            1.22 (0.26)                 3.40 (2.03--5.69)
  Mother's educational level                                                                                                 .003        
                                                                     None (vs High school/University)        0.61 (0.80)                 1.84 (0.38--8.88)
                                                                     Primary (vs High school/University)     0.53 (0.80)                 1.70 (0.35--8.20)
                                                                     Secondary (vs High school/University)   -1.18 (1.05)                0.31 (0.04--2.41)
  HBV infected mother                                                                                                        .008        
                                                                     Yes (vs No/Unknown)                     1.51 (0.45)                 4.52 (1.89--10.84)
  HBV infected siblings                                                                                                      .002        
                                                                     Yes (vs No/Unknown)                     1.53 (0.40)                 4.61 (2.13--10.01)
  HBV infected other family member                                                                                           .004        
                                                                     Yes (vs No/Unknown)                     1.35 (0.39)                 3.86 (1.80--8.30)
  Gynaecological examination in Turkey or unsafe male circumcision                                                           .032        
                                                                     Yes (vs No)                             0.41 (0.19)                 1.51 (1.04--2.21)
  Dental treatment in Turkey                                                                                                 .049        
                                                                     Yes (vs No)                             0.40 (0.20)                 1.50 (1.01--2.21)
  Treatment with needles in Turkey                                                                                           .012        
                                                                     Yes (vs No)                             0.49 (0.19)                 1.63 (1.13--2.36)

Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: confidence interval; HBV: hepatitis B virus; FGM: first-generation migrants; SGM: second-generation migrants.

First-generation migrants: foreign-born individuals; second-generation migrants: individuals born in Belgium with foreign-born parents; unsafe male circumcision: collective circumcision and/or circumcision not carried out by medical doctor.

Multiple GEE analyses were also conducted for males and females separately as well as for FGM and SGM ([S1](#pone.0234740.s007){ref-type="supplementary-material"}--[S4](#pone.0234740.s010){ref-type="supplementary-material"} Tables). The final model for males and females included age (*p* = .006 and *p* \< .001), FGM (*p* \< .001 and *p* \< .001) and treatment with needles in Turkey (*p* = .030 and *p* = .003). In males, HBV infected siblings (*p* = .022) and circumcision not conducted by a medical doctor were additional independent risk factors.

Independent risk factors for recent or past HBV infection among FGM included age (*p* \< .001), HBV infected mother (*p* = .042), HBV infected siblings (*p* = .024), gynaecological examination in Turkey or unsafe male circumcision (*p* \< .001), and treatment with needles in Turkey (*p* = .003). Among SGM, risk factors included HBV infected other family member (*p* = .010) and treatment with needles in Turkey (*p* = .030).

Sixty-five patients with past or recent HBV infection had a family member with HBV infection: among seven (10.8%) patients only the partner was infected, 14 (21.5%) with HBV infected mother only, one (1.5%) with HBV infected father only, 16 (24.6%) with HBV infected siblings only, 19 (29.2%) had another family member with HBV infection, three (4.6%) with HBV infection among mother and siblings, one (1.5%) with HBV infected father and siblings, and four (6.2%) with HBV infected siblings and other family member. Therefore HBV infected mother could potentially explain 17/65 (26.2%) anti-HBc positive cases with a positive family history of HBV infection.

Chronic HBV infection {#sec013}
---------------------

Of the 26 HBsAg positive individuals, 19 were FGM, leading to a HBsAg prevalence of 3.0% (19/628) in FGM. Compared to females, male FGM had a higher prevalence of chronic HBV infection (5.5% (15/272) in males vs 1.1% (4/356) in females, *p* = .002).

Gender difference regarding chronic HBV infection was not seen in Turkish SGM, i.e. 1.5% (3/196) in males vs 1.6% (4/257) in females, *p* = 1.000. Overall, 1.5% (7/453) SGM were HBsAg positive; only one out of seven HBsAg positive SGM was born after 1987. This corresponds to a HBsAg positivity of 0.5% (1/190) and 2.3% (6/263) in those born after and before 1987, respectively, *p =* .135. All but one had HBV infection in the family: one with HBV infection in mother only, two with HBV infection in siblings only, one with HBV infection in another family member only and two with HBV infection in siblings and another family member.

[S5 Table](#pone.0234740.s011){ref-type="supplementary-material"} shows factors associated with chronic HBV infection in the weighted univariate GEE. From the weighted multiple GEE analyses as shown in [Table 4](#pone.0234740.t004){ref-type="table"}, it can be seen that older age (*p* = .022) and gynaecological examination in Turkey or unsafe male circumcision (*p* = .004) significantly increased the odds, while body piercing/tattooing/earlobe perforation in Turkey resulted in a lower odds of chronic HBV infection (*p* = .009).

10.1371/journal.pone.0234740.t004

###### Association of chronic HBV infection to different risk factors among the total study population (n = 1,081) (weighted multiple GEE).
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  Parameter                                                                                           Estimate (SE)   *p*-value   aOR (95% CI)
  ------------------------------------------------------------------ -------------------------------- --------------- ----------- --------------------
  (intercept)                                                                                         -5.28 (0.65)                
  Age group                                                                                                           .022        
                                                                     40--59 years (vs 18--39 years)   1.28 (0.64)                 3.59 (1.03--12.48)
                                                                     ≥ 60 years (vs 18--39 years)     1.49 (0.81)                 4.45 (0.90--21.92)
  Gynaecological examination in Turkey or unsafe male circumcision                                                    .004        
                                                                     Yes (vs No)                      1.48 (0.46)                 4.37 (1.78--10.71)
  Body piercing/tattooing/earlobe perforation in Turkey                                                               .009        
                                                                     Yes (vs No)                      -1.13 (0.57)                0.32 (0.11--0.99)

Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: confidence interval.

Unsafe male circumcision: collective circumcision and/or circumcision not carried out by medical doctor.

### Follow-up in patients with chronic HBV infection {#sec014}

Eleven of 26 chronically infected patients were unaware of their HBV status and the other 15 were already linked to care ([Fig 1](#pone.0234740.g001){ref-type="fig"}). Thus, the percentage of newly diagnosed HBsAg positive patients was 1.02% (11/1,081). Two patients were referred to another hospital, one could not be linked to care due to incorrect contact details and the remaining eight patients were seen at the Department of Gastroenterology and Hepatology of Hospital East-Limburg.

![Follow-up results in patients with chronic HBV infection.\
Abbreviations: HBV: hepatitis B virus; ALT: alanine aminotransferase.](pone.0234740.g001){#pone.0234740.g001}

Out of the 15 patients that were already linked to care, 11 were classified as HBeAg-negative chronic infection, three as HBeAg-negative chronic hepatitis and one with HBeAg-positive chronic hepatitis. Both patients referred to another hospital and the eight patients evaluated in our hospital were categorized into two groups according to the HBV DNA (≥ 2,000 IU/mL vs \< 2,000 IU/mL) and ALT level (\> 40 IU/L vs ≤ 40 IU/L) at the first visit ([Fig 1](#pone.0234740.g001){ref-type="fig"}). There was no evidence of cirrhosis or HCC on abdominal ultrasound. Advanced liver disease was suspected in one patient based on transient elastography value ≥ 10 kPa. However, liver biopsy revealed F1 (portal fibrosis without septa) and the presence of nonalcoholic steatohepatitis (NASH). Within one year follow-up, none of the ten newly HBsAg positive patients had an indication for antiviral treatment. Two patients were lost to follow-up after the first visit for reasons unknown.

Solely anti-HBs positive {#sec015}
------------------------

Regarding our question on HBV vaccination, a total of 22.2% (239/1,076) indicated to be vaccinated, 26.9% (289/1,076) were not vaccinated and history of HBV vaccination was unknown in the remaining 50.9% (548/1,076) participants. Among those with a history of vaccination (n = 239), 29 (12.1%) and 1 (0.4%) were anti-HBc positive and HBsAg positive, respectively.

Solely anti-HBs positivity in Turkish SGM born after 1987 was 72.1% (137/190), and was lower for those SGM born before 1987 (21.5%, 56/261), *p* \< .001. [S6 Table](#pone.0234740.s012){ref-type="supplementary-material"} shows factors associated with vaccination status in the weighted univariate GEE. For solely anti-HBs positivity (i.e. vaccination status), the final model included gender (*p* = .008), age group (*p* \< .001), ethnicity (*p* \< .001), mother's educational level (*p* = .007) and vaccination history (*p* \< .001) ([Table 5](#pone.0234740.t005){ref-type="table"}).

10.1371/journal.pone.0234740.t005

###### Association of vaccination status (solely anti-HBs positive) to different risk factors among the total study population with information on anti-HBs (n = 1,077) (weighted multiple GEE).
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  Parameter                                                             Estimate (SE)   *p*-value   aOR (95% CI)
  ---------------------------- ---------------------------------------- --------------- ----------- -------------------
  (intercept)                                                           1.50 (0.69)                 
  Gender                                                                                .008        
                               Male (vs Female)                         -0.54 (0.20)                0.58 (0.39--0.86)
  Age group                                                                             \< .001     
                               40--59 years (vs 18--39 years)           -1.30 (0.23)                0.27 (0.18--0.43)
                               ≥ 60 years (vs 18--39 years)             -1.74 (0.54)                0.18 (0.06--0.51)
  Ethnicity                                                                             \< .001     
                               FGM (vs SGM)                             -1.18 (0.22)                0.31 (0.20--0.47)
  Mother's educational level                                                            .007        
                               None (vs High school/University)         -1.51 (0.68)                0.22 (0.06--0.83)
                               Primary (vs High school/University)      -1.23 (0.68)                0.29 (0.08--1.11)
                               Secondary (vs High school/University)    -0.61 (0.69)                0.54 (0.14--2.11)
  Vaccination history                                                                   \< .001     
                               Not vaccinated/Unknown (vs Vaccinated)   -1.90 (0.21)                0.15 (0.10--0.22)

Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: confidence interval; FGM: first-generation migrants; SGM: second-generation migrants.

First-generation migrants: foreign-born individuals; second-generation migrants: individuals born in Belgium with foreign-born parents; unsafe male circumcision: collective circumcision and/or circumcision not carried out by medical doctor.

Susceptible for HBV infection {#sec016}
-----------------------------

Six months after the last inclusion, 19.1% (44/230 susceptible individuals with follow-up information on vaccination) of the participants susceptible for HBV infection initiated vaccination.

Discussion {#sec017}
==========

In addition to the screening of FGM, i.e. those born in Turkey, our study is one of the first hepatitis B screening projects in Europe targeting a substantial proportion of SGM, i.e. those born in Belgium with a foreign-born parent. First, we show that outreach testing was well-accepted in Turkish migrants. Although Turkish migrants could opt for screening during home visits or at the hepatology outpatient clinic, the majority (97%) were tested immediately after educational sessions in Islamic mosques and Turkish organizations.

Our finding of 3% HBsAg positivity in Turkish FGM is in line with previous findings reported in the Netherlands and Germany (HBsAg prevalence varying from 3--5%), and reflects the high prevalence in the country of origin \[[@pone.0234740.ref010], [@pone.0234740.ref012], [@pone.0234740.ref013], [@pone.0234740.ref020]\]. However, the 1.5% prevalence of chronic HBV infection in Turkish SGM is higher than the reported 0.7% HBsAg prevalence in native Belgians \[[@pone.0234740.ref006]--[@pone.0234740.ref008]\]. This finding is novel and might in part be explained by the interaction of high prevalence in the country of origin and suboptimal coverage by primary prevention strategies in the country of birth. None of the seven cases of SGM with chronic HBV infection in our study were born after 1999, which is the year universal HBV vaccination in infants was implemented in Belgium. However, although six HBsAg positive SGM were born before 1987, one was born between 1987 and 1999, a birth cohort that should have been covered by the catch-up vaccination in 10--13 year-olds since 1999. In this matter, lowest immunization coverage rates in Belgium were found in those born between 1990 and 1998 \[[@pone.0234740.ref021]\]. Moreover, prior studies indicated that non-European origin and low educational level of the mother were associated with a decreased odds of vaccination coverage in children \[[@pone.0234740.ref022], [@pone.0234740.ref023]\]. In our study, mother's educational level was associated with vaccination coverage.

In our Turkish migrant study population, HBV infection in the mother could potentially explain less than one third of the patients with past or recent HBV infection. HBV infection in siblings possibly accounted for another major part of past or recent HBV infection in our study. In Turkey, perinatal transmission of HBV infection is uncommon as HBeAg positivity in pregnant chronic HBV patients is very low \[[@pone.0234740.ref024]\]. The infection is mostly acquired in childhood through horizontal transmission, i.e. that occurring through non-sexual and non-parenteral contact beyond six months of age, in childhood and pre-adolescent period \[[@pone.0234740.ref015], [@pone.0234740.ref024]\]. In the Turkish families, most of the mothers are housewives and mostly stay at home as caretakers for the children. Although the mother is important for horizontal HBV transmission through non-sexual close contact, sibling-to-sibling horizontal transmission might also be an important route of HBV infection \[[@pone.0234740.ref025]--[@pone.0234740.ref027]\]. Siblings share the same environment, experience the same cultural and family traditions, which may be associated with increased risks of transmission.

Physicians from countries with a selective vaccination program targeting groups at risk of HBV infection only, instead of adding a universal vaccination program, should be aware of horizontal transmission through non-sexual close contact \[[@pone.0234740.ref028]\]. Children are more likely to have contact with each other's body fluid and are therefore at risk of horizontal transmission through non-sexual close contact. Skin lesions or sharing contaminated material such as towels, toothbrushes or razor blades has been shown to play a role in horizontal transmission through non-sexual close contact \[[@pone.0234740.ref024]\]. In this matter, sharing toothbrushes regularly was univariately associated with past or recent HBV infection in our study population. However, this association diminished when accounting for other risk factors. The most important independent risk factors for past or recent HBV infection found in our study were male gender, older age, being a FGM, low educational level of the mother, a family history of HBV infection, gynaecological examination in Turkey or unsafe male circumcision, dental treatment in Turkey and treatment with needles in Turkey. These findings are in line with previous studies conducted in Turkish migrants living in Europe and studies conducted in Turkey \[[@pone.0234740.ref012], [@pone.0234740.ref013], [@pone.0234740.ref020], [@pone.0234740.ref024], [@pone.0234740.ref025]\].

For a screening program aimed at secondary prevention of HBV infection, access to care is inevitable to reduce the economic burden of HBV-related complications. In Greece, it is estimated that less than half of the patients diagnosed with HBV were referred and received the appropriate care \[[@pone.0234740.ref029]\]. This number was between 40% and 66% in the USA \[[@pone.0234740.ref030]\]. Most screening projects provide data on the HBsAg prevalence but do not assess referral, disease stage and initiation of antiviral therapy. We showed a successful referral of more than 90% newly diagnosed patients with chronic HBV infection. The implementation of a pre-screening phase with awareness activities among general practitioners and delegates of Turkish organizations as well as the impact of educational meetings on the Turkish migrant population to make an informed decision to participate in screening, might explain the good compliance to referral \[[@pone.0234740.ref011]\]. Within one year of follow-up, all newly diagnosed patients had HBeAg-negative chronic infection based on normal ALT levels, low HBV DNA levels, HBeAg negative status and no significant fibrosis \[[@pone.0234740.ref031]\]. During follow-up, none had an indication for antiviral therapy, but continued monitoring was still recommended for risk of HBV reactivation, advanced liver disease and HCC, especially those with HBV DNA levels \> 2,000 IU/mL \[[@pone.0234740.ref031]--[@pone.0234740.ref033]\].

Less than one in five susceptible individuals initiated hepatitis B vaccination. This is lower than the reported 52--89% among migrant populations in the USA and might be explained by 1) dissimilar populations, 2) free of charge vaccination or vaccination at a reduced price and 3) the use of a combination of letters, phone calls, e-mail and in-person appointments to contact susceptible individuals for vaccination in these studies \[[@pone.0234740.ref011], [@pone.0234740.ref034]--[@pone.0234740.ref038]\]. This is in contrast to our study, in which susceptible individuals were invited by a letter to consult their general practitioner for hepatitis B vaccination in accordance with standard practices in Belgium. The uptake of vaccination was also low (22%) in an outreach screening project among Chinese migrants in the Netherlands \[[@pone.0234740.ref039]\].

This study had a few limitations. First, this study could be underpowered to find significant associations between certain risk factors and hepatitis B viral markers, as sample size calculation was performed in such a way that the distribution per age group was similar to that of the Turkish population in Middle Limburg. Second, although a face-to-face questionnaire could limit the risk of misinterpretation and incomplete entries, certain socially undesirable behaviours could have been underreported. In this matter, the questionnaire did not cover questions regarding intravenous drug use, men who have sex with men and multiple unsafe heterosexual contacts since the answers to these questions are ought to be unreliable in this Turkish population in which the majority of people identify with Islam. Third, this study describes the results of hepatitis B screening and risk factor assessment in the Turkish population in Middle Limburg, Belgium. It is unknown whether observations from our study could be extrapolated for the European region. However, the collection of several sociodemographic factors and HBV risk factors in the current study allow a detailed characterization of the study population and consequently in-depth comparisons with other studies could be established.

In conclusion, we found that outreach testing and referral to specialist care was clinically effective in the Turkish migrant population. We confirmed that HBV prevalence among Turkish FGM reflects the high prevalence in the country of origin. An important finding was the relatively high infection prevalence in Turkish SGM compared with prevalence estimates for the general population in Belgium and other European countries. Given WHO's ambitious goal to eliminate viral hepatitis by 2030, national HBV screening for Turkish FGM should be implemented and might be considered in SGM not covered by primary prevention strategies, taking into account the asymptomatic nature of disease and misleading normal levels of ALT. Screening projects aimed at SGM are needed to further inform future screening policies for this population.
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Answer: We changed accordingly.

2\. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (a) whether consent was informed and (b) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

Answer: Minors were not included in the current study as stated under Patients and methods. In the methods section we included the following sentence: All participants gave their informed consent in writing prior to inclusion. (see lines 210-211)

3\. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

Answer: We used separate questionnaires for men and women, available in Dutch and Turkish language as previously stated in the manuscript. In addition to the original questionnaires we now provide the English version as supporting information (see S1 -- S6 Figs).

4\. Please ensure you have thoroughly discussed any potential limitations of this study within the Discussion section.

Answer: Study limitations are now depicted within the discussion section as follows: This study had a few limitations. First, this study could be underpowered to find significant associations between certain risk factors and hepatitis B viral markers, as sample size calculation was performed in such a way that the distribution per age group was similar to that of the Turkish population in Middle Limburg. Second, although a face-to-face questionnaire could limit the risk of misinterpretation and incomplete entries, certain socially undesirable behaviours could have been underreported. In this matter, the questionnaire did not cover questions regarding intravenous drug use, men who have sex with men and multiple unsafe heterosexual contacts since the answers to these questions are ought to be unreliable in this Turkish population in which the majority of people identify with Islam. Third, this study describes the results of hepatitis B screening and risk factor assessment in the Turkish population in Middle Limburg, Belgium. It is unknown whether observations from our study could be extrapolated for the European region. However, the collection of several sociodemographic factors and HBV risk factors in the current study allow a detailed characterization of the study population and consequently in-depth comparisons with other studies could be established. (see lines 425-439)

5\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

Answer: Data will be made available in the following repository: Koc, ÖM et al. (2020), Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium., Dryad, Dataset, <https://doi.org/10.5061/dryad.4f4qrfj87>
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Answer: We have included captions for our 11 supporting files at the end of our manuscript. The citations were changed in line with the PLOS ONE requirements.

Editor Comments:

Thanks for sending the paper intitled: \"Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium\". This paper reports the prevalence of HBV infection in individuals with a Turkish background (FGM and SGM), the results of a questionnaire on risk factors, and the follow-up of patients referred to care. The data is well presented and technically sounds.

Each reviewer made comments to this revision that should be answered.

1\. I also recommend to include more information regarding population recruitment in methods section.

Answer: For the interpretation of the study, we included the following sentence: In brief, educational hepatitis B sessions with the possibility for immediate HBV screening were scheduled after the regular meetings of Turkish organizations (e.g. Islamic mosque) located in Middle Limburg. Turkish migrants could also contact the culturally targeted, multilingual (Dutch‐, English‐ and Turkish‐speaking) first author for home visits and/or for an appointment at the hepatology outpatient clinic to sign an informed consent and be screened for HBV infection. (see lines 146-151)

Reviewer\#1:

The study is extremely relevant. Since immigrants are key populations in the elimination of HBV. These populations are often neglected and access to information and effective prevention and treatment is not provided to them. It is important to highlight the inclusion of those born in Belgium to immigrant parents. For, the customs, culture and prejudice against this population continue in this generation, which may favor a transmission network that needs to be interrupted in terms of global public health.

1\. I did not find the part of the title \"Early detection of chronic hepatitis B\" interesting.

Why do you think it was early detection? It would only be more correct, detection of chronic hepatitis B.

Answer: Our hepatitis B screening targeted at the Turkish migrant population is a form of secondary prevention aimed to reduce the impact of HBV infection. This is done by detecting HBV infection as soon as possible to prevent disease progression. It is well known that a chronically infected hepatitis B patient has no or minimal symptoms until the development of serious late complications such as cirrhosis, decompensated cirrhosis and hepatocellular carcinoma. Since none of the newly diagnosed hepatitis B patients in the current study had cirrhosis at presentation, we would like to underline the importance of early detection.

2\. The summary does not speak of the most important risk factors found in the study.

Answer: You are correct. We included the most important risk factors in the summary. (see lines 65-69)

3\. In the introduction: line 92-94. Paragraph 3 is confused. Are you talking about all countries in general, or where did the study take place?

Answer: This is a general statement indicating that migrants from endemic regions (HBsAg positivity 2-7.99% for intermediate endemic regions and \>8% for high endemicity) are an important risk group in regions with low endemicity for hepatitis B (HBsAg positivity \<2%), such as Western Europe.

4\. The questions reported in lines 137-139 are very important for the analysis of HBV risk factors, due to sexual and parenteral transmission. Despite being very particular factors, they need to be taken into account. They should be highlighted as limitations of the study and in an upcoming study to be evaluated.

This should be noted, that these factors were not considered to be risky, as the necessary information was not obtained.

Answer: We agree with the reviewer that information regarding intravenous drug use and high-risk sexual behavior is very important for the analysis of HBV risk factors. However, this information was not collected since the answers to these sensitive questions are probably unreliable in the Turkish migrant population in which the majority are Muslims.
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Answer: HBsAg positivity was considered as chronic HBV infection in the current study. All HBsAg patients were also anti-HBc positive. Considering the prospective follow-up of HBsAg positive individuals, we indeed confirmed that they were chronically infected with HBV infection.
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